Abstract

Apolipoprotein E (apoE) is a ligand for the low density lipoprotein receptor (LDLR) and the low density lipoprotein receptor-related protein (LRP). The aim of the present study was to clarify the role of hepatically localized apoE in the rapid initial removal of chylomicron remnants by using the isolated perfused liver. Radiolabeled chylomicron remnants were perfused in a single nonrecirculating pass into the livers of C57BL/6J (wild-type) mice, apoE-knockout mice, and apoE/LDLR-knockout mice for a period of 20 min. Aliquots of the perfusate leaving the liver were collected at regular intervals and the rate of removal of radioactivity was determined. At a trace concentration of chylomicron remnants (0.05 μg of protein per ml), wild-type mouse livers removed at a steady state of 50–55% of total chylomicron remnants perfused per pass; livers from apoE-knockout mice had the same capacity as wild-type mouse livers. When the concentration of remnants was increased to 12 μg of protein per ml, a level at which it has been shown that LDL receptor and LRP are near saturation, the capacity of the wild-type mouse livers to remove chylomicron remnants was decreased to 10–25% per pass, confirming that the removal mechanisms were nearing saturation. However, instead of finding a greater reduction in the removal rates or impairment in chylomicron remnant removal, livers from apoE-knockout mice were just as efficient as those from wild-type mice in removing remnants. Livers of mice that lacked both apoE and the LDLR also had a similar rate of removal at relatively low remnant concentrations (0.05–0.5 μg/ml), but had reduced capacity in removing remnants at a relatively high concentration (4–12 μg/ml) of chylomicron remnants (~20% per pass). The rate of removal at these concentrations, however, was similar to that attributed to the LRP in previous studies. Chylomicron remnants, whose apolipoproteins were disrupted by trypsinization, were removed at a normal rate by wild-type mouse livers but there was almost no removal by apoE-knockout mouse livers. At higher concentrations, however, the removal of apolipoprotein-disrupted chylomicron remnants was decreased. Our present findings do not support the hypothesis that hepatically localized apoE is a critical factor in the rapid initial removal of chylomicron remnants by either of the major pathways but do suggest that hepatically localized apoE can be added to lipoproteins to accelerate their uptake, although this process may have a limited capacity to compensate for apoE deficiency on lipoproteins.—Yu, K. C-W., Y. Jiang, W. Chen, and A. D. Cooper. Rapid initial removal of chylomicron remnants by the mouse liver does not require hepatically localized apolipoprotein E. J. Lipid Res. 2000. 41: 1715–1727.

Highlights

  • Apolipoprotein E is a ligand for the low density lipoprotein receptor (LDLR) and the low density lipoprotein receptor-related protein (LRP)

  • The absence of Apolipoprotein E (apoE) or the presence of defective forms of apoE can result in type III hyperlipoproteinemia, which is the accumulation of very low density lipoprotein (VLDL) remnants and chylomicron remnants in the plasma [2, 9]

  • Ji, Sanan, and Mahley [31] showed that the plasma clearance and hepatic uptake of exogenous apoE-enriched chylomicron remnants and apoE-enriched ␤-VLDL in vivo were impaired in mice after the intravenous administration of heparinase. van Dijk et al [35] found that higher than normal serum levels of apoE were required for non-LDLR-mediated pathways, in particular, the catabolism of VLDL remnants

Read more

Summary

Introduction

Apolipoprotein E (apoE) is a ligand for the low density lipoprotein receptor (LDLR) and the low density lipoprotein receptor-related protein (LRP). This modification is postulated to involve the acquisition of additional apoE that is produced by the hepatocytes [26, 27] that are localized in the space of Disse [28] bound to HSPG on the cell surface [29] This hypothesis is based on in vitro studies that tested ␤-very low density lipoproteins (␤-VLDL)(26, 30, 31), a cholesterol-enriched remnant lipoprotein of intestinal and hepatic origin [32]. Ji, Sanan, and Mahley [31] showed that the plasma clearance and hepatic uptake of exogenous apoE-enriched chylomicron remnants and apoE-enriched ␤-VLDL in vivo were impaired in mice after the intravenous administration of heparinase (which releases HSPG from the cell surface). Borensztajn and colleagues [36, 37] proposed that there are pathways for remnant lipoprotein removal that are independent of apolipoproteins but involve phospholipolysis, presumably mediated by lipoprotein or hepatic lipase

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.